Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV
about
Animal models for SARS and MERS coronavirusesHuman coronaviruses: insights into environmental resistance and its influence on the development of new antiseptic strategiesCurrent advancements and potential strategies in the development of MERS-CoV vaccinesChimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV.The M, E, and N structural proteins of the severe acute respiratory syndrome coronavirus are required for efficient assembly, trafficking, and release of virus-like particles.A replication-incompetent Rift Valley fever vaccine: chimeric virus-like particles protect mice and rats against lethal challengeA structural analysis of M protein in coronavirus assembly and morphology.Production and immunogenicity of chimeric virus-like particles containing the spike glycoprotein of infectious bronchitis virus.Vaccine potential of Nipah virus-like particlesA 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunityImmunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus.Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidatePeptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine.SARS vaccines: where are we?Analyses of Coronavirus Assembly Interactions with Interspecies Membrane and Nucleocapsid Protein ChimerasVaccines against Middle East respiratory syndrome coronavirus for humans and camels.Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice.
P2860
Q26799857-67DC0016-CD2F-41D2-B7D1-DC4FCCD24E7FQ27011643-742DDF4B-5FA7-4A80-8A4E-68F48754A67CQ27012578-4738AE93-30B5-4EF7-9D58-B68D6877F743Q30404941-9E751EB8-01CD-4FF7-9298-00AA06159DCEQ30484261-8978A2BA-81FC-4BFA-B6BE-3E8F53BCD9CFQ33621078-8A460110-0F98-4D4B-9AF1-0F33F34A9039Q33763099-F0216CEA-DD9A-469D-BA71-EA990FBF144DQ33865400-E1E7DE69-EA78-4049-A376-9E65ECD87B44Q33873756-24F79432-FB53-4EEB-8726-FEC398FB3358Q33904997-2CF06EB7-23DF-4762-8575-36B0CE72258EQ34247261-7F26280B-07D9-4AC9-91C9-26C0256FBA47Q37174550-78A85FF4-8BB5-4336-8D2B-AE1014DD4E08Q37373733-84814EF9-D85F-4486-92DB-C5D9A5487CF1Q37524036-DB713321-ADFE-4533-AC3E-606B3A7E8559Q38793264-554282D7-3DEA-4E8F-8E00-1CB946E70E67Q38992327-D4EADA59-7CBC-40FA-BE11-319E21B93862Q39102732-2D49D85F-247E-4081-B5D5-8AD0353D48F9Q40744757-AF20B69E-82FE-4C23-BB14-8D2022C90AA9
P2860
Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@ast
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@en
type
label
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@ast
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@en
prefLabel
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@ast
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@en
P2093
P2860
P1433
P1476
Chimeric coronavirus-like part ...... ce against challenge with SCoV
@en
P2093
C J Peters
Chien-Te Kent Tseng
Douglas M Watts
Naoko Yoshikawa-Iwata
Patrick Newman
Philip R Wyde
P2860
P304
P356
10.1016/J.VACCINE.2007.11.092
P407
P577
2007-12-26T00:00:00Z